Radius IPO to raise up to $68.3m to support Phase III osteoporosis trials
This article was originally published in Scrip
Executive Summary
Radius Health has set a preliminary price range of $8.50 to $10.50 per share for its initial public offering, which would raise $55.3-$68.3 million through the sale of 6.5 million shares to finance the development of the Cambridge, Massachusetts-based company's osteoporosis drugs.